MNX1 and cancer: The results of meta-analysis indicated elevated MNX1-AS1 level closely correlated with poorer overall survival (OS) (HR = 1.97, 95% CI, 1.73–2.24; P < 0.00001), and disease-free survival (DFS) (HR = 2.24, 95% CI, 1.48–3.38; P = 0.0001) in cancers, which was confirmed by the bioinformatics analysis.